FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society

Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society
EN
12/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amicus Therapeutics Inc.

 PRESS RELEASE

Amicus Therapeutics Announces Third Quarter 2025 Financial Results an...

Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended September 30, 2025. “Amicus achieved yet another impressive qu...

 PRESS RELEASE

Amicus Therapeutics to Present at Upcoming Investor Conferences in Nov...

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. 2025 UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 2:45 p.m. ETJefferies Global Healthcare Conference 2025 in London, U.K. on Tuesday, November 18, 2025, at 4:30 p.m. GMT A live audio webcast of each presentation can also be accessed via the investors se...

 PRESS RELEASE

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results o...

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss financial results for the quarter ended September 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the eve...

 PRESS RELEASE

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® ...

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) at the International Congress of Inborn Errors of M...

 PRESS RELEASE

Amicus Therapeutics to Present at Upcoming Investor Conferences in Sep...

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcare Conference 2025 in New York, NY, on Wednesday, September 3, 2025, at 10:20 a.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference 2025 in New York, NY on Tuesday, September 9, 2025, at 3:20 p.m. ET A live audio webcast of each presentation can also be accessed via ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch